Company / Operating Income
CUMBERLAND PHARMACEUTICALS INC Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$1.3M
FY2025
5-year range
-$9.6M / $1.3M
FY2021-FY2025
Trend
+113.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 10 years, ranging from -$10M in FY2024 to $4M in FY2016.
Based on SEC 10-K filings.
$1M in FY2025.
Improved from -$6M to $1M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 113.5% year-over-year.
- Peak operating income was recorded in FY2016.
- Lowest operating income in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3M | +113.5% |
| FY2024 | -$9.6M | -67.5% |
| FY2023 | -$5.7M | +25.7% |
| FY2022 | -$7.7M | +17.3% |
| FY2021 | -$9.3M | -45.5% |
| FY2020 | -$6.4M | +31.3% |
| FY2019 | -$9.3M | -548.1% |
| FY2018 | -$1.4M | -228.9% |
| FY2017 | $1.1M | -68.8% |
| FY2016 | $3.6M | +193.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026